Cannabinoid Abuse and Addiction: Clinical and Preclinical Findings

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 6, 2015, Pages 616-627

  Panlilio, L V ^a   Goldberg, S R ^a   Justinova, Z ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANANDAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CANNABINOID; CANNABIS; CHOLINERGIC RECEPTOR STIMULATING AGENT; CNR1 PROTEIN; DRONABINOL; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; KAPPA OPIATE RECEPTOR ANTAGONIST; N (3 PYRIDAZINYL) 4 [3 (5 TRIFLUOROMETHYL 2 PYRIDINYLOXY)BENZYLIDENE] 1 PIPERIDINECARBOXAMIDE; NABILONE; NEUROLEPTIC AGENT; OPIATE ANTAGONIST; PRODYNORPHIN; PROTEIN; RIMONABANT; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; KYNURENINE 3 MONOOXYGENASE;

ANXIETY; ATAXIA; ATTENTION DISTURBANCE; AUDITORY HALLUCINATION; BRONCHODILATATION; CANNABIS ADDICTION; CANNABIS SMOKING; COGNITIVE DEFECT; CONDITIONING; DECISION MAKING; DELUSION; DEPERSONALIZATION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG DISCRIMINATION; DRUG SELF ADMINISTRATION; DSM-5; DYSPHORIA; ELEVATED BLOOD PRESSURE; EUPHORIA; EX VIVO STUDY; GENETIC VARIABILITY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INCREASED APPETITE; INTERPERSONAL COMMUNICATION; LAUGHTER; LEARNING; MEMORY DISORDER; MENTAL INSTABILITY; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; MOTOR COORDINATION; NAUSEA; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; NIGHTMARE; NONHUMAN; NUCLEUS ACCUMBENS; NYSTAGMUS; ORGANIC BRAIN SYNDROME; PANIC; PARANOIA; PLACE PREFERENCE; PRIORITY JOURNAL; RELAPSE; RESPONSE TIME; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SHORT TERM MEMORY; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL IDEATION; TACHYCARDIA; TALKATIVENESS; THORAX PAIN; TIME PERCEPTION; TOBACCO USE; VENTRAL TEGMENTUM; VENTROLATERAL PREFRONTAL CORTEX; VOMITING; WELLBEING; WITHDRAWAL SYNDROME; WORKING MEMORY; XEROSTOMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DISCRIMINATION LEARNING; MARIJUANA ABUSE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CANNABINOIDS; DISCRIMINATION LEARNING; HUMANS; KYNURENINE 3-MONOOXYGENASE; MARIJUANA ABUSE; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84961710269     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.118     Document Type: Review

References (75)

1. Vandrey, R., Dunn, K.E., Fry, J.A. & Girling, E.R. A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend. 120, 238-241 (2012).
2. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Temporary placement of four synthetic cannabinoids into Schedule I. Final order. Fed. Regist. 79, 7577-7582 (2014).
3. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48. HHS Publication No. (SMA) 14-4863. (Substance Abuse and Mental Health Services Administration, Rockville, MD, 2014).
4. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515-527 (2009).
5. Niesink, R.J. & Van Laar, M.W. Does cannabidiol protect against adverse psychological effects of THC? Front. Psychiatry 4, 130 (2013).
6. Sevigny, E.L. Is today's marijuana more potent simply because it's fresher? Drug Test. Anal. 5, 62-67 (2013).
7. Van Amsterdam, J., Brunt, T. & Van Den Brink, W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J. Psychopharmacol. 29, 254-263 (2015).
8. Spaderna, M., Addy, P.H. & D'Souza, D.C. Spicing things up: Synthetic cannabinoids. Psychopharmacology (Berl). 228, 525-540 (2013).
9. Castaneto, M.S., Gorelick, D.A., Desrosiers, N.A., Hartman, R.L., Pirard, S. & Huestis, M.A. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 144, 12-41 (2014).
10. Karila, L. et al. Acute and long-term effects of cannabis use: A review. Curr. Pharm. Des. 20, 4112-4118 (2014).
11. Johns, A. Psychiatric effects of cannabis. Br. J. Psychiatry 178, 116-122 (2001).
12. Hall, W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 110, 19-35 (2015).
13. Hartman, R.L. & Huestis, M.A. Cannabis effects on driving skills. Clin. Chem. 59, 478-492 (2013).
14. Volkow, N.D., Baler, R.D., Compton, W.M. & Weiss, S.R. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219-2227 (2014).
15. Hall, W. & Degenhardt, L. The adverse health effects of chronic cannabis use. Drug Test. Anal. 6, 39-45 (2014).
16. Cadet, J.L., Bisagno, V. & Milroy, C.M. Neuropathology of substance use disorders. Acta Neuropathol. 127, 91-107 (2014).
17. Volkow, N.D. et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc. Natl. Acad. Sci. USA 111, E3149-E3156 (2014).
18. Le Strat, Y., Dubertret, C. & Le Foll, B. Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. Accid. Anal. Prev. 76, 1-5 (2015).
19. Agrawal, A., Budney, A.J. & Lynskey, M.T. The co-occurring use and misuse of cannabis and tobacco: A review. Addiction 107, 1221-1233 (2012).
20. Colizzi, M. et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology 40, 640-649 (2015).
21. Hughes, J.R., Fingar, J.R., Budney, A.J., Naud, S., Helzer, J.E. & Callas, P.W. Marijuana use and intoxication among daily users: An intensive longitudinal study. Addict. Behav. 39, 1464-1470 (2014).
22. Haney, M. et al. Predictors of marijuana relapse in the human laboratory: Robust impact of tobacco cigarette smoking status. Biol. Psychiatry 73, 242-248 (2013).
23. Hasin, D.S. et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am. J. Psychiatry 170, 834-851 (2013).
24. Cooper, Z.D. & Haney, M. Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. Int. Rev. Psychiatry 21, 104-112 (2009).
25. Gorelick, D.A. et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. 123, 141-147 (2012).
26. Haney, M. The marijuana withdrawal syndrome: Diagnosis and treatment. Curr. Psychiatry Rep. 7, 360-366 (2005).
27. Allsop, D.J. et al. Quantifying the clinical significance of cannabis withdrawal. PloS One 7, e44864 (2012).
28. Goldman, M. et al. Reward-related brain response and craving correlates of marijuana cue exposure: A preliminary study in treatment-seeking marijuana-dependent subjects. J. Addict. Med. 7, 8-16 (2013).
29. Balter, R.E., Cooper, Z.D. & Haney, M. Novel pharmacologic approaches to treating cannabis use disorder. Curr. Addict. Rep. 1, 137-143 (2014).
30. Budney, A.J., Roffman, R., Stephens, R.S. & Walker, D. Marijuana dependence and its treatment. Addict. Sci. Clin. Pract. 4, 4-16 (2007).
31. Levin, F.R., Mariani, J.J., Brooks, D.J., Pavlicova, M., Cheng, W. & Nunes, E.V. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 116, 142-150 (2011).
32. Haney, M., Cooper, Z.D., Bedi, G., Vosburg, S.K., Comer, S.D. & Foltin, R.W. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38, 1557-1565 (2013).
33. Huggins, J.P., Smart, T.S., Langman, S., Taylor, L. & Young, T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 1837-1846 (2012).
34. Huestis, M.A. et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl). 194, 505-515 (2007).
35. Le Foll, B., Gorelick, D.A. & Goldberg, S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl). 205, 171-174 (2009).
36. Justinova, Z., Tanda, G., Munzar, P. & Goldberg, S.R. The opioid antagonist naltrexone reduces the reinforcing effects of delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl). 173, 186-194 (2004).
37. Cooper, Z.D. & Haney, M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl). 211, 141-148 (2010).
38. Haney, M., Hart, C.L., Vosburg, S.K., Comer, S.D., Reed, S.C. & Foltin, R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 197, 157-168 (2008).
39. Mason, B.J. et al. A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37, 1689-1698 (2012).
40. Gray, K.M. et al. A double-blind randomized controlled trial of Nacetylcysteine in cannabis-dependent adolescents. Am. J. Psychiatry 169, 805-812 (2012).
41. Marshall, K., Gowing, L., Ali, R. & Le Foll, B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst. Rev. 12, CD008940 (2014).
42. Fratta, W. & Fattore, L. Molecular mechanisms of cannabinoid addiction. Curr. Opin. Neurobiol. 23, 487-492 (2013).
43. Hoffman, A.F. & Lupica, C.R. Synaptic targets of D9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb. Perspect. Med. 3, a012237 (2013).
44. Covey, D.P., Wenzel, J.M. & Cheer, J.F. Cannabinoid modulation of drug reward and the implications of marijuana legalization. Brain Res. (2014); e-pub ahead of print 25 November 2014.
45. Tanda, G., Munzar, P. & Goldberg, S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 3, 1073-1074 (2000).
46. Martellotta, M.C., Cossu, G., Fattore, L., Gessa, G.L. & Fratta, W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85, 327-330 (1998).
47. Lefever, T.W., Marusich, J.A., Antonazzo, K.R. & Wiley, J.L. Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model. Pharmacol. Biochem. Behav. 118, 30-35 (2014).
48. Mendiz-abal, V., Zimmer, A. & Maldonado, R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology 31, 1957-1966 (2006).
49. Justinova, Z., Tanda, G., Redhi, G.H. & Goldberg, S.R. Selfadministration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 169, 135-140 (2003).
50. Justinova, Z. et al. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 33, 2870-2877 (2008).
51. Justinova, Z., Solinas, M., Tanda, G., Redhi, G.H. & Goldberg, S.R. The endogenous cannabinoid anandamide and its synthetic analog R(1)-methanandamide are intravenously self-administered by squirrel monkeys. J. Neurosci. 25, 5645-5650 (2005).
52. Justinová, Z., Yasar, S., Redhi, G.H. & Goldberg, S.R. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously selfadministered by squirrel monkeys. J. Neurosci. 31, 7043-7048 (2011).
53. Spano, M.S., Fattore, L., Cossu, G., Deiana, S., Fadda, P. & Fratta, W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br. J. Pharmacol. 143, 343-350 (2004).
54. Deiana, S. et al. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology 52, 646-654 (2007).
55. Lecca, D., Cacciapaglia, F., Valentini, V. & Di Chiara, G. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (Berl). 188, 63-74 (2006).
56. Lepore, M., Vorel, S.R., Lowinson, J. & Gardner, E.L. Conditioned place preference induced by delta 9-tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward. Life Sci. 56, 2073-2080 (1995).
57. Carvalho, A.F., Reyes, A.R., Sterling, R.C., Unterwald, E. & Van Bockstaele, E.J. Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology (Berl). 211, 479-491 (2010).
58. Hyatt, W.S. & Fantegrossi, W.E. D9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behav. Pharmacol. 25, 253-257 (2014).
59. Maldonado, R. Study of cannabinoid dependence in animals. Pharmacol. Ther. 95, 153-164 (2002).
60. Solinas, M., Scherma, M., Tanda, G., Wertheim, C.E., Fratta, W. & Goldberg, S.R. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J. Pharmacol. Exp. Ther. 321, 1127-1134 (2007).
61. Solinas, M., Zangen, A., Thiriet, N. & Goldberg, S.R. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur. J. Neurosci. 19, 3183-3192 (2004).
62. Zangen, A., Solinas, M., Ikemoto, S., Goldberg, S.R. & Wise, R.A. Two brain sites for cannabinoid reward. J. Neurosci. 26, 4901-4907 (2006).
63. Aceto, M.D., Scates, S.M., Lowe, J.A. & Martin, B.R. Dependence on delta 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J. Pharmacol. Exp. Ther. 278, 1290-1295 (1996).
64. Marusich, J.A., Lefever, T.W., Antonazzo, K.R., Craft, R.M. & Wiley, J.L. Evaluation of sex differences in cannabinoid dependence. Drug Alcohol Depend. 137, 20-28 (2014).
65. Beardsley, P.M. & Martin, B.R. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after delta(9)-tetrahydrocannabinol withdrawal. Eur. J. Pharmacol. 387, 47-53 (2000).
66. McMahon, L.R. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with delta9-tetrahydrocannabinol. Psychopharmacology (Berl). 188, 306-314 (2006).
67. Solinas, M., Panlilio, L.V. & Goldberg, S.R. Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: A self-administration study in rats. Neuropsychopharmacology 29, 1301-1311 (2004).
68. Panlilio, L.V., Solinas, M., Matthews, S.A. & Goldberg, S.R. Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. Neuropsychopharmacology 32, 646-657 (2007).
69. Panlilio, L.V., Zanettini, C., Barnes, C., Solinas, M. & Goldberg, S.R. Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology 38, 1198-1208 (2013).
70. Degenhardt, L. et al. Does the 'gateway' matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. Psychol. Med. 39, 157-167 (2009).
71. Carriba, P. et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32, 2249-2259 (2007).
72. Justinov-a, Z. et al. Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addict. Biol. 16, 405-415 (2011).
73. Justinová, Z., Redhi, G.H., Goldberg, S.R. & Ferré, S. Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on D9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys. J. Neurosci. 34, 6480-6484 (2014).
74. Solinas, M. et al. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J. Neurosci. 27, 5615-5620 (2007).
75. Justinova, Z. et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat. Neurosci. 16, 1652-1661 (2013).